Key Takeaways
Exelixis (NASDAQ: EXEL) is experiencing strong commercial momentum, largely propelled by its established oncology powerhouse, Cabometyx (cabozantinib), and a recent label expansion into neuroendocrine tumors (NETs). The company reported $2.123 billion in revenue for 2025 and has provided optimistic 2026 guidance, with a midpoint of roughly $2.4 billion. This projected growth underscores the enduring strength of its renal cell carcinoma (RCC) franchise and the promising early uptake in the newly approved NET indication.
The FDA approved Cabometyx for adult and pediatric patients with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET) and extra-pancreatic neuroendocrine tumors (epNET) in March 2025. This approval followed positive results from the CABINET trial, where Cabometyx demonstrated a significant improvement in progression-free survival (PFS) compared to placebo in both pNET (median PFS 13.8 months vs. 3.3 months) and epNET (median PFS 8.5 months vs. 4.2 months) cohorts. This new indication alone represents an estimated $1 billion oral segment market opportunity, which Exelixis aims to penetrate aggressively.
Management views its business through distinct "franchises" – RCC, colorectal cancer (CRC), and NETs – with an ambition to achieve market leadership in each. Cabometyx, already approved in seven indications, remains a cornerstone of this strategy, providing a stable revenue base while the company invests in its next-generation pipeline. This dual-pronged approach, leveraging a mature asset while nurturing new ones, is critical for sustained growth in the competitive oncology landscape.
The company’s focus on these core franchises, combined with its strong financial performance, has positioned it favorably. With a current market capitalization of $11.41 billion and a healthy P/E ratio of 15.59, Exelixis trades at a reasonable valuation for a biotech firm with significant near-term catalysts. Investors are keenly watching the upcoming first-quarter 2026 financial results on May 5, 2026, which will offer further insights into the continued performance of Cabometyx and the initial trajectory of the NET launch.
Exelixis' next-generation tyrosine kinase inhibitor (TKI), zanzalintinib, is rapidly emerging as a pivotal asset, with its most immediate catalyst being a potential U.S. FDA approval in metastatic colorectal cancer (CRC). The company recently announced that the FDA accepted its New Drug Application (NDA) for zanzalintinib in combination with an immune checkpoint inhibitor for patients with metastatic CRC, with a PDUFA date set for December 2026. This submission follows positive results from the Phase 3 STELLAR-303 trial, which evaluated zanzalintinib plus atezolizumab (Tecentriq) against regorafenib.
Detailed results from STELLAR-303, presented at ESMO 2025 and published in The Lancet, showed that the zanzalintinib combination improved median overall survival (OS) to 10.9 months compared to 9.4 months with regorafenib in the intent-to-treat population. This represented a significant 20% reduction in the risk of death. While the OS benefit in the non-liver metastases subgroup remains immature, Exelixis expects a more mature look at this data in mid-2026, hoping for a positive outcome to bolster its commercial messaging across all patient groups.
The potential approval in CRC is particularly significant as it represents a commercially important, chemo-free, checkpoint-containing regimen for late-line patients. This could offer a much-needed new treatment option in a challenging disease setting. Exelixis is already preparing for a potential zanzalintinib launch later this year in CRC, highlighting the company's confidence in the drug's profile and market opportunity.
Zanzalintinib also boasts a more favorable pharmacokinetic (PK) profile compared to cabozantinib, with a shorter half-life of "a little under 24 hours" versus cabozantinib's approximately four-day half-life. This improved PK profile is expected to make dose holds and symptom resolution periods more manageable for patients, potentially enhancing its utility in combination therapies and improving overall patient compliance and tolerability. This could be a key differentiator in a crowded oncology market, making zanzalintinib a more "user-friendly" option for clinicians.
Beyond its imminent potential in colorectal cancer, zanzalintinib is central to Exelixis' ambitious "second wave" expansion strategy, targeting multiple high-value oncology indications. The company has broadened zanzalintinib's development program to include seven pivotal studies, spanning both genitourinary (GU) and gastrointestinal (GI) cancers, which management believes could unlock a $5 billion opportunity. This aggressive pipeline expansion is critical for Exelixis to diversify its revenue streams and establish zanzalintinib as a multi-indication blockbuster.
A key upcoming catalyst is the topline data expected in mid-2026 from STELLAR-304, a frontline non-clear cell renal cell carcinoma (nccRCC) study. This Phase 3 trial is comparing zanzalintinib plus nivolumab (Opdivo) against sunitinib (Sutent) in a patient population that has historically lacked large randomized trials. NccRCC accounts for 15% to 20% of all RCC cases, representing a significant unmet medical need. Exelixis aims to generate "level one evidence" to establish a new standard of care, differentiating zanzalintinib across response rates, PFS, and ideally overall survival.
Another promising indication is neuroendocrine tumors (NETs), where STELLAR-311 is evaluating zanzalintinib against everolimus (Afinitor) in first-line patients. This Phase 2/3 trial has a primary completion date of June 2029, positioning zanzalintinib to potentially build upon Cabometyx's recent success in this market. The company also has a strategic collaboration with Merck & Co. for LITESPARK-033, a Phase 3 trial testing zanzalintinib plus belzutifan (Welireg) against Cabometyx in RCC patients who have previously received PD-(L)1 inhibitors. This trial, with a primary completion date in February 2032, highlights zanzalintinib's potential to compete even with Exelixis' own flagship product in certain settings.
Furthermore, Exelixis plans to initiate three more trials this year: STELLAR-316 in adjuvant CRC for MRD-positive patients, STELLAR-201 (Phase 2) in meningioma monotherapy, and an additional RCC study with belzutifan. This extensive clinical program underscores Exelixis' commitment to maximizing zanzalintinib's potential across a broad spectrum of cancers, leveraging its improved PK profile for enhanced combination therapy options and patient management.
The renal cell carcinoma (RCC) treatment landscape is highly competitive and rapidly evolving, presenting both opportunities and challenges for Exelixis' Cabometyx and its pipeline asset, zanzalintinib. At recent medical conferences like ASCO GU, the debate around combining versus sequencing therapies in RCC has intensified. Exelixis has actively engaged in this discussion, particularly in response to data from trials like Merck’s LITESPARK-011, which evaluated belzutifan plus lenvatinib. While LITESPARK-011 showed a PFS benefit, it lacked mature overall survival (OS) data, leading Exelixis to characterize it as "not practice-changing."
Exelixis argues that tolerability concerns and the clinical value of a "TKI break" may favor sequencing approaches over immediate combination therapies. The company highlighted that combination regimens can add significant toxicity, with approximately 40% of patients discontinuing at least one agent in some studies. This high discontinuation rate underscores the importance of patient management and the potential advantage of zanzalintinib's shorter half-life, which could make combinations and dose adjustments more manageable. Cabometyx has established itself as a leader in RCC, and Exelixis believes its strong efficacy profile, coupled with the flexibility of sequencing, will help it maintain its market position against emerging combinations.
The company’s strategy involves not only defending Cabometyx's market share but also strategically positioning zanzalintinib to capture new segments. The LITESPARK-033 trial, in partnership with Merck, directly compares zanzalintinib plus belzutifan against Cabometyx in post-PD-(L)1 RCC patients. This head-to-head comparison demonstrates Exelixis' confidence in zanzalintinib's potential to offer a superior or differentiated profile even against its own successful drug. The outcome of such trials will be crucial in shaping future treatment paradigms and market share dynamics.
Ultimately, overall survival (OS) remains the gold standard in oncology, and Exelixis believes that OS data will be the determining factor in whether new combinations truly supplant established sequencing strategies. The company's deep expertise in RCC, combined with its dual-asset strategy (Cabometyx and zanzalintinib), positions it to navigate this complex competitive environment. By focusing on both efficacy and patient tolerability, Exelixis aims to reinforce its leadership in RCC while expanding into new treatment algorithms.
Beyond the immediate catalysts surrounding Cabometyx and zanzalintinib, Exelixis is actively cultivating a diverse and promising early-stage pipeline, which is essential for its long-term growth trajectory and sustained innovation in oncology. The company's strategy involves both internal development and strategic external partnerships, leveraging its expertise in kinase inhibitors and expanding into novel modalities like antibody-drug conjugates (ADCs) and bispecific antibodies. This broader pipeline aims to target an expanding range of tumor types and indications, ensuring future revenue diversification.
One notable early-stage asset is XL309, a USP1 inhibitor currently in Phase 1 development for solid tumors. USP1 inhibitors represent a novel mechanism of action, targeting DNA damage repair pathways, which could be particularly effective in specific cancer types. Similarly, XB010, a next-generation 5T4-MMAE ADC, is also in Phase 1 for solid tumors, with ongoing evaluation in combination with pembrolizumab. ADCs are a rapidly advancing class of therapeutics, offering targeted delivery of cytotoxic agents to cancer cells, and XB010 could become a significant asset if successful.
Exelixis is also exploring immunotherapeutic approaches with XB628, a PD-L1 + NKG2A bispecific antibody in Phase 1 for solid tumors. Bispecific antibodies are designed to engage multiple targets simultaneously, potentially enhancing anti-tumor immune responses. Another ADC in the pipeline is XB371, a next-generation TF-TOPOi ADC, also in Phase 1. These diverse mechanisms of action reflect Exelixis' commitment to exploring cutting-edge science to address unmet needs in cancer treatment.
Furthermore, Exelixis has an exclusive clinical development and option agreement with Sairopa B.V. for ADU-1805, a SIRPα-targeting mAb. This asset is in Phase 1 for solid tumors, with an option for Exelixis to acquire it pending certain Phase 1 results. Such partnerships allow Exelixis to expand its pipeline without bearing the full upfront development costs, while gaining access to innovative technologies. This multi-pronged pipeline, spanning various targets and modalities, underscores Exelixis' ambition to remain at the forefront of cancer care for decades to come.
Exelixis presents a compelling investment case, underpinned by solid financial fundamentals and a pipeline brimming with potential catalysts. The company's trailing twelve months (TTM) financial metrics highlight its operational efficiency and profitability: a remarkable gross margin of 96.4%, an operating margin of 37.6%, and a net margin of 33.7%. These figures demonstrate Exelixis' ability to convert revenue into substantial profits, a hallmark of a well-managed pharmaceutical company.
From a growth perspective, Exelixis delivered robust performance in fiscal year 2025, with revenue growth of 7.0%, net income soaring by 50.1%, and EPS increasing by 58.0% year-over-year. Over a longer horizon, the company has shown impressive cumulative growth per share, with revenue up 70.5% over three years and 166.7% over five years, while net income surged 408.3% and 694.7% respectively over the same periods. This consistent growth trajectory, driven by Cabometyx and new indications, bodes well for future shareholder value.
Valuation-wise, Exelixis trades at a P/E ratio of 15.59 and a P/S ratio of 4.92, which appear reasonable given its growth prospects and profitability. The company also boasts a strong balance sheet, with a current ratio of 3.56 and a debt-to-equity ratio of 0.08, indicating ample liquidity and minimal leverage. Analyst consensus points to a "Buy" rating, with an average price target of $45.71, slightly above its current price of $44.93. The high target of $54.00 suggests significant upside potential if zanzalintinib's clinical and regulatory milestones are met.
However, investors should remain cognizant of the inherent risks in the biotech sector, including clinical trial failures, regulatory setbacks, and intense market competition. While zanzalintinib's PDUFA date for CRC is a major near-term event, its success is not guaranteed, and the competitive landscape in RCC remains fierce. Despite these risks, Exelixis' strong financial health, diversified pipeline, and clear strategic vision for its oncology franchises position it as an attractive opportunity for long-term growth investors.
Exelixis stands at a pivotal juncture, with its established Cabometyx franchise providing a solid foundation and zanzalintinib poised to unlock significant new market opportunities. The upcoming PDUFA date for zanzalintinib in CRC and critical Phase 3 data readouts in nccRCC could be transformative catalysts. Investors should monitor these developments closely, as Exelixis continues its ambitious pursuit of market leadership in oncology.
Want deeper research on any stock? Try Kavout Pro for AI-powered analysis, smart signals, and more. Already a member? Add credits to run more research.
